Parenthood for Childhood Hodgkin Lymphoma Survivors

News
Article

Women who were treated for Hodgkin lymphoma during childhood and adolescence had similar rates of post-treatment parenthood as that of the general population.

Women who were diagnosed with and treated for Hodgkin lymphoma during childhood and adolescence had similar rates of post-treatment parenthood as that of the general female population, according to the results of a German study published in Lancet Oncology.

“Women who have had treatment for Hodgkin lymphoma before age 18 years can be reassured that pregnancy is possible, and that they are likely to give birth to a healthy child,” wrote Jürgen H. Brämswig, MD, of University Children’s Hospital in Münster, Germany, and colleagues.

The study looked at 467 female survivors of Hodgkin lymphoma diagnosed at age 18 years or younger. All patients included in the study had to have 5 years of follow-up, be in continuous complete remission, and have no second malignancy or Hodgkin lymphoma relapse before parenthood occurred. These survivors were compared with the German female population aged 16 to 49 years.

The median follow-up of patients was 20.4 years. Of the patients, 228 (49%) had 406 children. The cumulative incidence of parenthood was 67%.

“In our sample of Hodgkin lymphoma survivors, a median of 1.78 children were born per mother, which is slightly higher than the 1.33 live births reported in the Childhood Cancer Survivor Study (CCSS),” the researchers wrote.

The researchers found no difference in the incidence of parenthood among the survivors and the general population at any point except for 66 women aged 40 to 44 years at the time of last follow-up. These women had significantly lower incidences of parenthood compared with the general population (61% vs 78%; P = .001) for reasons that the researchers said were not well understood.

“Forty-three (65%) of the 66 patients aged 40–44 years were long-term survivors of the two earliest trials, HD-78 and HD-82. They received higher doses of chemotherapy than did patients in the other three studies, especially those in the HD-78 study, which administered four to six cycles of COPP chemotherapy [cyclophosphamide, vincristine, procarbazine, and prednisone] in therapy groups 2 and 3, high doses of radiotherapy to the involved field (36–40 Gy), and a random assignment of 36–40 Gy or 18–20 Gy to adjacent fields in therapy groups 1–3,” the researchers wrote. “Because of these factors, women treated with the early protocols HD-78 and HD-82 might have been hesitant to become pregnant because the long-term side effects, including fertility, parenthood, and the health of children, were unknown.”

When looking at the effects of various treatments on likelihood of parenthood, the researchers found that parenthood was significantly reduced among those women who had been treated with pelvic radiation compared with those treated with abdominal or supradiaphragmatic radiation (hazard ratio [HR] = 0.76, 95% confidence interval [CI], 0.61–0.95; P = .01). No effect or only minor effects on parenthood were found for procarbazine in cumulative doses up to 11,400 mg/m², cyclophosphamide in cumulative doses up to 6,000 mg/m², alkylating agent dose scores of 1 to 5, therapy group based on disease stage at diagnosis, abdominal and supradiaphragmatic radiation, and age at treatment.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content